Courtney

John is Founder and Managing Director of Infusion Pharma Consulting LLC, a leading business strategy consultancy focused on the Orphan Drug and Hospital Therapeutics

Dr. Liu shares the consensus that CMT is a lesser known disease and more research is needed to shed light on the experiences of patients with CMT.

After her genetic diagnosis, Joy connected with HNF for advice on AFOs and a letter writing campaign to tell family and friends about her diagnosis.

Allison Moore founded HNF in 2001 in an effort to improve the quality of life for people with Charcot-Marie-Tooth.

HNF has invited Dr. Coté to lead the discussion on Public Policy. We will cover issues such as better AFO (leg-bracing) options, fast-tracking drug discoveries and clinical trials, applying for disability benefits, Medicare/Medicaid and services.

We’ve invited Dr. David Walk to join the panel discussion on “Genotype and Phenotype: Managing Symptoms, The Role of Researchers/Clinicians.”

Don’t wait, reserve your spot at the first Patient-Centered CMT Summit!

Leaders in Charcot-Marie-Tooth research need to be progressive visionaries, willing and able to push the boundaries to explore every opportunity available to advance therapeutics and clinical trials for CMT.

Matt Downing, a CMT1A patient, will join HNF’s Founder and CEO Allison Moore in a panel discussion on the good, the bad, and the benefits of participating in a clinical trial.

Advocating for her own health, Kim was able to harness the power of genetic information to devise a treatment plan that not only reduced, but reversed much of her disability with CMT.